Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04886908
Other study ID # CHUB-BOULAKHRIF
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 9, 2021
Est. completion date July 28, 2021

Study information

Verified date March 2022
Source Brugmann University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity. The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.


Recruitment information / eligibility

Status Completed
Enrollment 373
Est. completion date July 28, 2021
Est. primary completion date July 28, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients. Exclusion Criteria: Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Data extraction from medical files
Data extraction from medical files

Locations

Country Name City State
Belgium CHU Brugmann Brussels

Sponsors (1)

Lead Sponsor Collaborator
Brugmann University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Age Age of the patient at the time of diagnose 5 minutes
Primary Sex Sex of the patient 5 minutes
Primary Name of the department in which the patient is followed Ophthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital 5 minutes
Primary Tumor anatomical location Eyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone. 5 minutes
Primary Tumor size Tumor size in millimeters 5 minutes
Primary Laterality Laterality: left, right, median 5 minutes
Primary Multiple or single tumor Multiple or single tumor 5 minutes
Primary Primitive tumor or recidive Primitive tumor or recidive 5 minutes
Primary Risk factor: phototype Phototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns. 5 minutes
Primary Risk factor: immunosuppression (yes/no) Pathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma 5 minutes
Primary Risk factor: keratosis Actinic keratosis of the face 5 minutes
Primary Risk factor: solar exposition (yes/no) Lived in a sunny European country> 1 year, lived in a sunny country outside Europe> 1 year, sunbed use> 1 session, history of solar erythema during childhood. 5 minutes
Primary Diagnosis Time between the appearance of the tumor and the first consultation 5 minutes
Primary Locoregional extension report (yes/no) Locoregional extension report (yes/no) 5 minutes
Primary Histological diagnosis of the tumor Histological diagnosis of the tumor 5 minutes
Primary Healthy or invaded margins Healthy or invaded margins 5 minutes
Primary Superficial or infiltrating tumor Superficial or infiltrating tumor 5 minutes
Primary Diagnostic method Diagnostic method: curettage, punch, biopsy, flattening 5 minutes
Primary Surgical management method Biopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen 5 minutes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05779423 - Cryoablation+Ipilimumab+Nivolumab in Melanoma Phase 2
Terminated NCT01468818 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma Phase 2
Completed NCT01820234 - Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event N/A
Completed NCT00535769 - Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use Phase 0
Completed NCT00526032 - Melanoma Detection by Oblique-Incidence Optical Spectroscopy N/A
Completed NCT00588341 - Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Phase 2
Active, not recruiting NCT01447199 - The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
Enrolling by invitation NCT04758988 - AI Augmented Training for Skin Specialists N/A
Not yet recruiting NCT04534868 - Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area N/A
Recruiting NCT04138342 - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer Phase 1
Completed NCT03673917 - Cosmetology Students and Skin Cancer N/A
Recruiting NCT04341064 - Sun-safe Habits Intervention and Education Phase 3
Completed NCT04206995 - Cancer Sensing: Evaluation of Odour Sampling Techniques
Recruiting NCT05574101 - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Phase 2
Not yet recruiting NCT05860881 - Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) Phase 3
Completed NCT05146622 - Virtual Sun Safe Workplaces Ph I
Recruiting NCT05068310 - Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
Recruiting NCT03889899 - Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. N/A